WO1998017284A2 - Inhibition of cap-independent protein synthesis and hiv-tar translation by heparin or heparin mimetics, and methods for gene therapy - Google Patents
Inhibition of cap-independent protein synthesis and hiv-tar translation by heparin or heparin mimetics, and methods for gene therapy Download PDFInfo
- Publication number
- WO1998017284A2 WO1998017284A2 PCT/CA1997/000794 CA9700794W WO9817284A2 WO 1998017284 A2 WO1998017284 A2 WO 1998017284A2 CA 9700794 W CA9700794 W CA 9700794W WO 9817284 A2 WO9817284 A2 WO 9817284A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heparin
- translation
- hiv
- cap
- tar
- Prior art date
Links
- 229960002897 heparin Drugs 0.000 title claims abstract description 85
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims abstract description 84
- 229920000669 heparin Polymers 0.000 title claims abstract description 84
- 230000014616 translation Effects 0.000 title claims abstract description 84
- 238000013519 translation Methods 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims abstract description 19
- 238000001243 protein synthesis Methods 0.000 title claims abstract description 19
- 238000001415 gene therapy Methods 0.000 title claims abstract description 6
- 230000005764 inhibitory process Effects 0.000 title claims description 22
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 19
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 10
- 229920002477 rna polymer Polymers 0.000 claims abstract description 9
- 239000002299 complementary DNA Substances 0.000 claims abstract description 8
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 32
- 241000700605 Viruses Species 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 239000002502 liposome Substances 0.000 claims description 13
- 230000008685 targeting Effects 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 5
- -1 N-acetyl- glucosaminyl Chemical group 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000006656 viral protein synthesis Effects 0.000 claims description 3
- 101000601610 Drosophila melanogaster Heparan sulfate N-sulfotransferase Proteins 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
- 208000031886 HIV Infections Diseases 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000000284 extract Substances 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 14
- 241000725303 Human immunodeficiency virus Species 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 12
- 230000001419 dependent effect Effects 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 230000001086 cytosolic effect Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 241000991587 Enterovirus C Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000001995 reticulocyte Anatomy 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 241000710188 Encephalomyocarditis virus Species 0.000 description 4
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 4
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000036647 reaction Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- IQFYYKKMVGJFEH-BIIVOSGPSA-N 2'-deoxythymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-BIIVOSGPSA-N 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- 241000724256 Brome mosaic virus Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100035549 Eukaryotic translation initiation factor 2 subunit 1 Human genes 0.000 description 1
- 101710151743 Eukaryotic translation initiation factor 2 subunit 1 Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 102000010982 eIF-2 Kinase Human genes 0.000 description 1
- 108010037623 eIF-2 Kinase Proteins 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000037039 plant physiology Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009712 regulation of translation Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the invention relates to the use of heparin and heparin mimetic compounds thereof to inhibit cap-independent protein synthesis (or translation) in addition to cap-dependent protein synthesis and to inhibit translation of HIV TAR-containing messenger ribonucleic acids (mRNA) mediated.
- mRNA messenger ribonucleic acids
- Heparin is among the best studied glycosamino- glycans. This compound is known for its involvement in a variety of physiological processes. It is involved in the control of homeostasis, smooth muscle proliferation, growth factors activity, extracellular matrix integrity, among others (Margalit, H. et al . (1993) Journal of Biological Chemistry 268: 19228-19231). Heparin is a negatively charged polymer of a regular disaccharide repeat sequence with a high degree of sul- fatation. Thus, many proteins are expected to bind heparin via electrostatic interactions, but electrostatic forces by themselves are probably not sufficient (Margalit, H. et al. (1993) Journal of Biological Chem- istry 268: 19228-19231).
- RNA-dependent eIF-2 ⁇ protein kinase Phosphorylation of the alpha subunit of eIF-2 leads to the inhibition of the cap-dependent translation ( In : Translational control (1996). Edited by John W.B. Hershey et al., Cold Spring Harbor Laboratory Press, Cold Spring Har- bor, N.Y. USA. pp. 31-69 and 139-172).
- picornaviruses such as poliovirus or encephalomyocarditis virus
- mRNAs In : Translational control (1996) Edited by John W.B. Her- shey et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. USA. pp. 549-573
- other RNAs such as BiP mRNA or Antennapedia mRNA
- Translational control (1996) Edited by John W.B. Hershey et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. USA. pp.
- HIV-1 human immunodeficiency virus type 1
- TAR trans-acting responsive region
- the TAR sequence is therefore located at the 5' end of all viral mRNAs. It has been proposed that the TAR sequence and flanking 3' region played a role in the regulation of translation of HIV-1 mRNAs by inhibiting this translation (Parkin, N.T. et al. (1988) EMBO Journal , 7:2831-2837).
- Heparin inhibits cap-independent translation, in addition to bind to and activate PKR and therefore inhibit cap-dependent translation. This inhibition of cap-independent translation does not necessarily imply the involvement of PKR.
- One aim of the present invention is to provide means to inhibit cap-independent protein synthesis or translation.
- One aim of the present invention is to provide means to inhibit translation of HIV TAR-containing messenger ribonucleic acids (mRNA) .
- mRNA messenger ribonucleic acids
- Another aim of the present invention is to provide means to inhibit cap-independent protein synthesis or translation in addition to cap-dependent protein synthesis .
- heparin and heparin mimetic compounds thereof to inhibit cap-independent protein syn- thesis or translation in addition to cap-dependent protein synthesis.
- use of heparin and heparin mimetic compounds thereof to inhibit translation of HIV TAR-containing messenger ribonucleic acids (mRNA) in accordance with the present invention there is provided a method of inhibiting cap-independent protein synthesis of eukaryotic cells, which comprises adding heparin or heparin mimetics thereof to the eukaryotic cells.
- a method of inhibiting translation of HIV TAR-containing messenger ribonucleic acids (mRNA) of HIV infected eukaryotic cells which comprises adding heparin or heparin mimetics thereof to the infected eukaryotic cells.
- mRNA messenger ribonucleic acids
- Such a heparin mimetic include, without limitation, sulfated polysaccharides .
- a pharmaceutical composition for the therapeutical inhibition of cap-independent protein synthe- sis in a patient suffering from a viral infection which comprises a therapeutic amount of heparin and/or heparin mimetics thereof in association with a pharmaceutical carrier.
- the carrier may be a liposome or a biovector .
- a pharmaceutical composition for the therapeutical inhibition of translation of HIV TAR-containing messenger ribonucleic acids (mRNA) in a patient HIV-infected which comprises a therapeutic amount of heparin and/or heparin mimetics thereof in association with a pharmaceutical carrier.
- the carrier may be a liposome or a biovector.
- composition for gene therapy of patients infected with a virus which comprises administering to — b —
- the patient an expression vector consisting of a cDNA sequence coding for enzyme glycosaminoglycan N-acetyl- glucosaminyl N-deacetylase/N-sulfotransferase with a constitutive or inducible promoter operatively linked upstream of the cDNA sequence, the expression vector is adapted to express the enzyme thereby reducing viral protein synthesis in the patient.
- the expression vector may be a recombinant virus selected from the group consisting of adenovirus and retrovirus for targeting of the infected cells.
- the delivery vector may be a liposome for targeting of the infected cells.
- Fig. 1 illustrates a fluorography of radiola- belled polypeptides synthesized in vi tro in a rabbit reticulocyte lysate in accordance with the method of the present invention
- Fig. 2 illustrates a fluorography of radiola- belled polypeptides synthesized in vi tro in a Krebs ascites fluid in accordance with the method of the present invention
- Fig. 3 illustrates a fluorography of radiola- belled polypeptides synthesized in vi tro in a cytoplas- mic extract obtained from eukaryotic cells in accordance with the method of the present invention
- Fig. 4 illustrates a fluorography of radiola- belled polypeptides synthesized in vi tro in a cytoplas- mic extract obtained from eukaryotic cells that have grown as monolayers;
- Fig. 5 illustrates a scheme of potential targeting of virally infected cells using heparin or heparin mimetics thereof in accordance with the present invention.
- heparin inhibits:
- ds double-stranded RNA-dependent protein kinase
- a method of inhibiting cap-independent protein synthesis of eukaryotic cells which comprises adding heparin or heparin mimetics thereof to the eukaryotic cells.
- a method of inhibiting translation of mRNAs containing the TAR structure from HIV-1 at their 5 ' end comprises adding heparin or heparin mimetics thereof to the eukaryotic cells.
- the method of inhibiting translation of mRNAs containing the TAR structure is intended to be used also for HIV-2, since HIV-2 has also a TAR structure.
- a pharmaceutical composition for the therapeutical inhibition of cap-independent protein synthesis in a patient suffering from a viral infection which comprises a therapeutic amount of heparin and/or heparin mimetics thereof in association with a pharmaceutical carrier.
- the carrier may be a liposome or a biovector.
- a pharmaceutical composition for the thera-Guinical inhibition of TAR (HIV-1) synthesis in a HIV-1 infected patient which comprises a therapeutic amount of heparin and/or heparin mimetics thereof in association with a pharmaceutical carrier.
- the carrier may be a liposome or a biovector.
- vi tro protein syntheses were performed by employing a rabbit reticulocyte lysate from commercial source (Promega), and a Krebs ascites fluid, by following the manufacturer's instructions or currently employed procedures, respectively. Furthermore, a cyto- plasmic extract obtained from eukaryotic cells has been generated by following a method described by Skup, D. et al. ((1977) Nucleic Acids Research 4: 3581-3587). To label the newly-synthesized polypeptides during 1-hour- incubation reactions, ⁇ s-methionine (Amersham; >1200 Ci/mmol) was employed.
- RNAs were either a) transcribed in vi tro for the generation of a capped CAT (chloramphenycol)-EMC (IRES of encephalomyocarditis virus) -LUC (luciferase) mRNA as previously described (Pause, A. et al.
- the cytoplasmic extract employed for translation was obtained from monkey Cos-1 cells that have grown as monolayers.
- HIV-1 TAR-containing mRNA is capped TAR(+111)CAT RNA described by Parkin, N.T. et al . ((1988) EMBO Journal , 7:2831-2837).
- the 5' region of the latter mRNA corresponds to nucleotides +1 to +111 of HIV mRNAs and is transcribed from plasmid pSP64/TAR( +111 )CAT.
- cytoplasmic extract from BHK (baby hamster kidney) cells has been generated and in vitro translation reactions have been performed by following the method described by Skup and Millward (Skup, D. et al . (1977) Nucleic Acids Research 4: 3581-3587).
- the cytoplasmic extract has not been treated with micrococcal nuclease. Again, a drastic inhibition of both cap- dependent and cap-independent translation is observed, as mentioned above in section A) : as seen on this autoradiogram (Fig.
- virus replication inhibition by heparin or heparin mimetic compounds thereof have been shown to be restricted to the virus adsorption stage of the virus to the target cells (Taylor, D.L. et al. (1995) Antiviral Research 28: 159-173; Thormar, H. et al. (1995) Antiviral Research 27: 49-57; Banfield, B.W. et al. (1995) Virology 208: 531-539; Ida, H. et al. (1994) Antiviral Research 23: 143-159; Barzu, T. et al. (1993) Journal of medicinal Chemistry 36: 3546-3555; Hanssens, F.P. et al.
- heparin or heparin mimetics can be targeted by different means to cells that have been infected by viruses, the latter showing a cap- independent translation initiation and HIV TAR-mediated of their RNA.
- This targeting of heparin might be performed and mediated by biovectors or liposomes, for example, the latter vectors containing heparin or heparin mimetics. This targeting can be specific when one considers the strategy depicted in Fig. 5. Perspectives
- heparin should be incorporated into liposomes or biovectors which are then targeted to cells infected with various viruses by following the general procedure depicted in Fig. 5. 5) Targeting of any kind cell, not necessarily virus-infected, in which the cap-independent translation of any protein has to be inhibited.
- target cells are infected by viruses through ligand-receptor interactions.
- receptors are on the surface of the virus- infected cells and are recognized by the ligand of the virus .
- the ligand(s) of the virus has(ve) to be exposed at the cell surface of the infected cells (Fig. 5B).
- liposomes or biovectors containing heparin and/or hepa- rin mimetics and bearing the cell receptor at their surface will be generated. These liposomes or biovectors will selectively interact with the virus-infected cells through ligand-receptor interactions and will allow the transfer of the heparin and/or heparin mimet- ics into the virus-infected cells. This will inhibit the viral protein synthesis and render the virus to be avirulent (unable to synthesize the viral components, such as viral proteins).
- Heparin biosynthesis occurs only in connective tissue mast cells (Nader, H.B., and Dietrisch, in Heparin; Lane, D.A. and Lindahl, U, eds pp. 81-96, Arnold, London).
- the biosynthesis of heparin is initiated by glycosylation reactions that generate saccharide sequences composed of alternating D-glucuronic and N- acetylglucosamine (GlcNAc) units.
- GlcNAc N-deacetylation/N- sulfation of N-acetylglucosamine is a key event in the biosynthesis of heparin.
- the cDNA coding for a glycosaminoglycan N-acetylglucosami- nyl N-deacetylase/N-sulfotransferase is incorporated into a plasmid or any suitable DNA sequence under the control of a viral or an eukaryotic promoter, thus allowing transcription of the corresponding RNA in these cells.
- This promoter can be an inducible promoter or a constitutive promoter.
- Targeting of the cells in order to incorporate the glycosaminoglycan N-acetylglu- cosaminyl N-deacetylase/N-sulfotransferase cDNA can be performed by gene therapy using retroviral vectors, adenoviral vectors, or liposome-mediated gene delivery.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a method of inhibiting cap-independent protein synthesis of eukaryotic cells, which comprises adding heparin or heparin mimetics thereof to said eukaryotic cells. There is also disclosed a method of inhibiting translation of HIV TAR-containing messenger ribonucleic acids (mRNA) of HIV infected eukaryotic cells, which comprises adding heparin or heparin mimetics thereof to said eukaryotic cells. There is also disclosed a composition for gene therapy using glycosaminoglycan N-acetylglycosaminyl N-deacetylase/N-sulfotransferase cDNA.
Description
INHIBITION OF CAP-INDEPENDENT PROTEIN SYNTHESIS BY HEPARIN OR HEPARIN MIMETICS THEREOF
BACKGROUND OF THE INVENTION
( ) Field of the Invention The invention relates to the use of heparin and heparin mimetic compounds thereof to inhibit cap-independent protein synthesis (or translation) in addition to cap-dependent protein synthesis and to inhibit translation of HIV TAR-containing messenger ribonucleic acids (mRNA) mediated.
(b) Description of Prior Art
Heparin is among the best studied glycosamino- glycans. This compound is known for its involvement in a variety of physiological processes. It is involved in the control of homeostasis, smooth muscle proliferation, growth factors activity, extracellular matrix integrity, among others (Margalit, H. et al . (1993) Journal of Biological Chemistry 268: 19228-19231). Heparin is a negatively charged polymer of a regular disaccharide repeat sequence with a high degree of sul- fatation. Thus, many proteins are expected to bind heparin via electrostatic interactions, but electrostatic forces by themselves are probably not sufficient (Margalit, H. et al. (1993) Journal of Biological Chem- istry 268: 19228-19231).
Recently, the substitution of heparin for double-stranded (ds) RNA in the autophosphorylation of the interferon-inducible, RNA-dependent eIF-2α protein kinase (PKR) has been analyzed in detail (George, C.X. et al. (1996) Virology 221: 180-188). Phosphorylation of the alpha subunit of eIF-2 leads to the inhibition of the cap-dependent translation ( In : Translational control (1996). Edited by John W.B. Hershey et al., Cold Spring Harbor Laboratory Press, Cold Spring Har- bor, N.Y. USA. pp. 31-69 and 139-172).
Internal initiation, or cap-independent translation, is known to occur with picornaviruses (such as poliovirus or encephalomyocarditis virus) mRNAs ( In : Translational control (1996) Edited by John W.B. Her- shey et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. USA. pp. 549-573), other RNAs such as BiP mRNA or Antennapedia mRNA ( In : Translational control (1996) Edited by John W.B. Hershey et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. USA. pp. 95-96), and might be involved during human immunodeficiency virus (HIV) infection (Svitkin et al. (1994) Journal of Virology 68, 7001-7007). Internal translation requires an internal ribosome entry site (IRES) on the mRNA. Recently, the inhibi- tion of IRES-mediated translation of poliovirus has been shown to be inhibited by a 60-nucleotide long yeast RNA (Das., S. et al. (1996) Journal of Virology 70: 1624-1632). To my knowledge, this is the only scientific report that has been published to date showing the specific and direct inhibition of cap-independent translation by a molecule, here an RNA.
Moreover, translation of mRNAs of human immunodeficiency virus type 1 (HIV-1) has been shown to be mediated by cis-acting sequences responsive to the tat gene product, the trans-acting responsive (TAR) region, which is located immediately adjacent to the site of transcription initiation (Rosen, CA. et al. (1985) Cell , 41:813-823). The TAR sequence is therefore located at the 5' end of all viral mRNAs. It has been proposed that the TAR sequence and flanking 3' region played a role in the regulation of translation of HIV-1 mRNAs by inhibiting this translation (Parkin, N.T. et al. (1988) EMBO Journal , 7:2831-2837). However, in the latter study, the authors, by translating HIV-1 TAR- containing mRNAs in a rabbit reticulocyte lysate or in
a cytoplasmic extract of eukaryotic HeLa cells that have grown in suspension cultures, or by microinjecting HIV-1 TAR-containing mRNAs in Xenopus oocytes, predict that the block to translation of viral mRNAs by their 5' untranslated region (UTR) must somehow be overcome to allow for efficient viral structural protein synthesis and viral replication during viral infection (Parkin, N.T. et al . (1988) EMBO Journal , 7:2831-2837). It would be highly desirable to be provided with means to inhibit cap-independent protein synthesis or translation.
It would be highly desirable to be provided with means to inhibit translation of HIV TAR-containing messenger ribonucleic acids (mRNA).
SUMMARY OF THE INVENTION
Heparin inhibits cap-independent translation, in addition to bind to and activate PKR and therefore inhibit cap-dependent translation. This inhibition of cap-independent translation does not necessarily imply the involvement of PKR.
One aim of the present invention is to provide means to inhibit cap-independent protein synthesis or translation. One aim of the present invention is to provide means to inhibit translation of HIV TAR-containing messenger ribonucleic acids (mRNA) .
Another aim of the present invention is to provide means to inhibit cap-independent protein synthesis or translation in addition to cap-dependent protein synthesis .
In accordance with the present invention there is provided the use of heparin and heparin mimetic compounds thereof to inhibit cap-independent protein syn- thesis or translation in addition to cap-dependent protein synthesis.
In accordance with the present invention there is provided the use of heparin and heparin mimetic compounds thereof to inhibit translation of HIV TAR-containing messenger ribonucleic acids (mRNA) . In accordance with the present invention there is provided a method of inhibiting cap-independent protein synthesis of eukaryotic cells, which comprises adding heparin or heparin mimetics thereof to the eukaryotic cells. In accordance with the present invention there is provided a method of inhibiting translation of HIV TAR-containing messenger ribonucleic acids (mRNA) of HIV infected eukaryotic cells, which comprises adding heparin or heparin mimetics thereof to the infected eukaryotic cells. Such a heparin mimetic include, without limitation, sulfated polysaccharides .
In accordance with the present invention there is provided a pharmaceutical composition for the therapeutical inhibition of cap-independent protein synthe- sis in a patient suffering from a viral infection, which comprises a therapeutic amount of heparin and/or heparin mimetics thereof in association with a pharmaceutical carrier. The carrier may be a liposome or a biovector . In accordance with the present invention there is provided a pharmaceutical composition for the therapeutical inhibition of translation of HIV TAR-containing messenger ribonucleic acids (mRNA) in a patient HIV-infected, which comprises a therapeutic amount of heparin and/or heparin mimetics thereof in association with a pharmaceutical carrier. The carrier may be a liposome or a biovector.
In accordance with the present invention there is provided a composition for gene therapy of patients infected with a virus, which comprises administering to
— b —
the patient an expression vector consisting of a cDNA sequence coding for enzyme glycosaminoglycan N-acetyl- glucosaminyl N-deacetylase/N-sulfotransferase with a constitutive or inducible promoter operatively linked upstream of the cDNA sequence, the expression vector is adapted to express the enzyme thereby reducing viral protein synthesis in the patient.
The expression vector may be a recombinant virus selected from the group consisting of adenovirus and retrovirus for targeting of the infected cells.
The delivery vector may be a liposome for targeting of the infected cells.
BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 illustrates a fluorography of radiola- belled polypeptides synthesized in vi tro in a rabbit reticulocyte lysate in accordance with the method of the present invention;
Fig. 2 illustrates a fluorography of radiola- belled polypeptides synthesized in vi tro in a Krebs ascites fluid in accordance with the method of the present invention;
Fig. 3 illustrates a fluorography of radiola- belled polypeptides synthesized in vi tro in a cytoplas- mic extract obtained from eukaryotic cells in accordance with the method of the present invention;
Fig. 4 illustrates a fluorography of radiola- belled polypeptides synthesized in vi tro in a cytoplas- mic extract obtained from eukaryotic cells that have grown as monolayers; and
Fig. 5 illustrates a scheme of potential targeting of virally infected cells using heparin or heparin mimetics thereof in accordance with the present invention.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention, the use of heparin inhibits:
(i) cap-independent translation and, (ii) translation of mRNAs containing the TAR structure from HIV-1 at their 5' end, in addition to bind to and activate the double-stranded (ds) RNA-dependent protein kinase PKR. This inhibition of cap-independent translation and HIV TAR-mediated translation does not necessarily imply the involvement of PKR.
In accordance with the present invention there is provided a method of inhibiting cap-independent protein synthesis of eukaryotic cells, which comprises adding heparin or heparin mimetics thereof to the eukaryotic cells.
In accordance with the present invention there is provided a method of inhibiting translation of mRNAs containing the TAR structure from HIV-1 at their 5 ' end, which comprises adding heparin or heparin mimetics thereof to the eukaryotic cells.
In accordance with the present invention, the method of inhibiting translation of mRNAs containing the TAR structure is intended to be used also for HIV-2, since HIV-2 has also a TAR structure.
In accordance with the present invention there is provided a pharmaceutical composition for the therapeutical inhibition of cap-independent protein synthesis in a patient suffering from a viral infection, which comprises a therapeutic amount of heparin and/or heparin mimetics thereof in association with a pharmaceutical carrier. The carrier may be a liposome or a biovector.
In accordance with the present invention there is provided a pharmaceutical composition for the thera-
peutical inhibition of TAR (HIV-1) synthesis in a HIV-1 infected patient, which comprises a therapeutic amount of heparin and/or heparin mimetics thereof in association with a pharmaceutical carrier. The carrier may be a liposome or a biovector. Materiel and methods A) Inhibition of cap-independent translation
In vi tro protein syntheses were performed by employing a rabbit reticulocyte lysate from commercial source (Promega), and a Krebs ascites fluid, by following the manufacturer's instructions or currently employed procedures, respectively. Furthermore, a cyto- plasmic extract obtained from eukaryotic cells has been generated by following a method described by Skup, D. et al. ((1977) Nucleic Acids Research 4: 3581-3587). To label the newly-synthesized polypeptides during 1-hour- incubation reactions, ^^s-methionine (Amersham; >1200 Ci/mmol) was employed. Heparin, which was resuspended in phosphate-buffered saline (PBS) and stored at room temperature, was obtained from a commercial source (Gibco BRL; catalog number 15077-019; 100000 units at 164 units per mg). Messenger RNAs were either a) transcribed in vi tro for the generation of a capped CAT (chloramphenycol)-EMC (IRES of encephalomyocarditis virus) -LUC (luciferase) mRNA as previously described (Pause, A. et al. (1994) Nature 371: 762-767), or b) from viral source, i.e.: from poliovirus (Mahoney strain) and from encephalomyocarditis virus. Analysis of the labeled polypeptides was performed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE). Gels were treated for fluorography with En3Hance (Dupont).
B) Inhibition of translation of mRNAs containing the TAR structure from HIV-1 at their 5 ' end
The cytoplasmic extract employed for translation was obtained from monkey Cos-1 cells that have grown as monolayers.
To label the newly-synthesized polypeptides during 1-hour-incubation reactions, -^^S-methionine (Amersham; >1200 Ci/mmol) was employed. Heparin, which was resuspended in phosphate-buffered saline (PBS) and stored at room temperature, was obtained from a commercial source (Gibco BRL; catalog number 15077-019).
HIV-1 TAR-containing mRNA is capped TAR(+111)CAT RNA described by Parkin, N.T. et al . ((1988) EMBO Journal , 7:2831-2837). The 5' region of the latter mRNA corresponds to nucleotides +1 to +111 of HIV mRNAs and is transcribed from plasmid pSP64/TAR( +111 )CAT.
Analysis of the labeled polypeptides was performed by sodium dodecyl sulfate ( SDS)-polyacrylamide gel electrophoresis (PAGE). Gels were treated for fluorography with En3Hance (Dupont). Results
A) Translation in rabbit reticulocyte lysate and in Krebs ascites fluid. As shown in the fluorography of Fig. 1 (rabbit reticulocyte lysate translation) and Fig. 2 (translation in Krebs ascites fluid), inhibition of both cap-dependent translation (as seen with incorporation of 35g-πιethionine into the CAT polypeptide) and cap-independent translation (as seen with incorporation of 5g-methionine into the LUC polypeptide) is reduced, an event dependent of the heparin concentration present in the reaction. Furthermore, translation of both the poliovirus and encephalomyocarditis virus polypeptide precursors are drastically reduced when 5 μg per μl of heparin is present in the translation reaction, when compared to the reactions that contain the viral RNAs
alone. Both extracts have been previously treated with micrococcal nuclease to hydrolyze the endogenous mRNAs, and the micrococcal nuclease has been inhibited with EGTA or pTp ( 2 ' deoxythymidine, 3 ' -5 ' -diphosphate) prior to the use of the extracts. 0.4 μg of CAT-EMC-LUC RNA and 0.2 μg of either EMC or poliovirus RNA were employed in 40 μl translation reactions.
B) Inhibition of cap-dependent translation in a cell extract obtained from eukaryotic cells that have grown in suspension cultures
A cytoplasmic extract from BHK (baby hamster kidney) cells has been generated and in vitro translation reactions have been performed by following the method described by Skup and Millward (Skup, D. et al . (1977) Nucleic Acids Research 4: 3581-3587). The cytoplasmic extract has not been treated with micrococcal nuclease. Again, a drastic inhibition of both cap- dependent and cap-independent translation is observed, as mentioned above in section A) : as seen on this autoradiogram (Fig. 3), 5 μg per μl of heparin totally abolishes translation of the CAT (translated in a cap- dependent fashion) and the LUC polypeptides (translated in a cap-independent fashion) in the translation reac- tion. This reveals that the initiation of their translation is inhibited. Translation of the latter polypeptides is recovered accordingly when the concentration of heparin is reduced in the reactions. 0.4 μg of CAT- EMC-LUC RNA was employed in 40 μl translation reac- tions.
C) Inhibition of HIV-1 TAR-mediated translation in a cytoplasmic extract obtained from cells that have grown as monolayers A cytoplasmic extract from monkey Cos-1 cells has been generated. The cytoplasmic extract has not been treated with micrococcal nuclease.
Interestingly, the capped TAR(+111)CAT RNA is very efficiently translated in this system (Fig. 4; lane 2 ) , when compared to the control reaction that was performed without exogenously added RNA (lane 1). This observed efficient synthesis of capped TAR(+111)CAT RNA is thus in contrast to the results obtained by others (Parkin, N.T. et al . (1988) EMBO Journal , 7:2831-2837). However, the translation of the capped TAR(+111) CAT RNA is drastically inhibited by heparin (lane 3: 1.25 μg per μl of translation reaction; lane 4: 0.125 μg per μl; lane 5: 0.0125 μg per μl; lane 6: 0.00125 μg per μl; in the latter case, translation of capped TAR(+111)CAT RNA is inhibited by more than 90% when compared to the translation performed in absence of heparin as shown in lane 2). Translation of capped TAR(+111)CAT RNA recovers when heparin is present at a concentration of 0.000125 μg per μl (lane 7).
0.4 μg of capped TAR(+111)CAT RNA was employed in 40 μl translation reactions (lanes 2 to 7). Discussion
To date, virus replication inhibition by heparin or heparin mimetic compounds thereof have been shown to be restricted to the virus adsorption stage of the virus to the target cells (Taylor, D.L. et al. (1995) Antiviral Research 28: 159-173; Thormar, H. et al. (1995) Antiviral Research 27: 49-57; Banfield, B.W. et al. (1995) Virology 208: 531-539; Ida, H. et al. (1994) Antiviral Research 23: 143-159; Barzu, T. et al. (1993) Journal of medicinal Chemistry 36: 3546-3555; Hanssens, F.P. et al. (1993) Journal of Virology 67: 4492-4496). One report mentions the in vi tro inhibition of translation of brome mosaic virus RNA in a wheat germ extract in presence of heparin, however an effect mediated by the plant homologue of PKR (pPKR) (Langland, J.O. et al. (1996) Plant Physiology and Biochemistry 34: 521-
526). To my knowledge, no report has been thus far published showing inhibition of cap-independent translation and HIV TAR-mediated translation by heparin or heparin mimetics either in vi tro or in vivo . Thus, my discovery has a great potential when one considers the fact that heparin or heparin mimetics can be targeted by different means to cells that have been infected by viruses, the latter showing a cap- independent translation initiation and HIV TAR-mediated of their RNA. This targeting of heparin might be performed and mediated by biovectors or liposomes, for example, the latter vectors containing heparin or heparin mimetics. This targeting can be specific when one considers the strategy depicted in Fig. 5. Perspectives
1) Potentially, any kind of cap-independent translation resulting on the attachment on RNA of ribosomes by internal ribosome entry could be reduced or inhibited with adequate concentrations of heparin or heparin mimetics thereof.
2) The effect of small heparin oligosaccharides of define lengths (as described in George, C.X. et al. (1996) Virology 221: 180-188) should be analyzed for their ability to reduce or inhibit the extent of cap- independent translation.
3 ) The effect of heparin or heparin mimetics on HIV-2 TAR-mediated translation of RNA should be analyzed.
4) Some experiments should be performed in vivo as well as in si tu: heparin should be incorporated into liposomes or biovectors which are then targeted to cells infected with various viruses by following the general procedure depicted in Fig. 5.
5) Targeting of any kind cell, not necessarily virus-infected, in which the cap-independent translation of any protein has to be inhibited.
The present invention will be more readily un- derstood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.
EXAMPLE I
Therapeutic treatment of virus-infected cells As shown in Fig. 5A, target cells are infected by viruses through ligand-receptor interactions. As depicted, receptors are on the surface of the virus- infected cells and are recognized by the ligand of the virus . To generate newly synthesized virus particles, the ligand(s) of the virus has(ve) to be exposed at the cell surface of the infected cells (Fig. 5B).
To selectively target the virus-infected cells liposomes or biovectors containing heparin and/or hepa- rin mimetics and bearing the cell receptor at their surface will be generated. These liposomes or biovectors will selectively interact with the virus-infected cells through ligand-receptor interactions and will allow the transfer of the heparin and/or heparin mimet- ics into the virus-infected cells. This will inhibit the viral protein synthesis and render the virus to be avirulent (unable to synthesize the viral components, such as viral proteins).
The above-described therapeutic treatment of virus-infected cells will be effective for any virus wherein its protein synthesis is cap-independent.
EXAMPLE II
Gene therapy using glycosaminoglycan N-acetylglucosami- nyl N-deacetylase/N-sulfotransferase cDNA
Heparin biosynthesis occurs only in connective tissue mast cells (Nader, H.B., and Dietrisch, in Heparin; Lane, D.A. and Lindahl, U, eds pp. 81-96, Arnold, London). The biosynthesis of heparin is initiated by glycosylation reactions that generate saccharide sequences composed of alternating D-glucuronic and N- acetylglucosamine (GlcNAc) units. N-deacetylation/N- sulfation of N-acetylglucosamine is a key event in the biosynthesis of heparin. This N-deacetylation/N sul- fation of GlcNAc is an obligatory step for the subsequent reactions for the biosynthesis of heparin. Recently, cDNAs coding for enzyme containing N- deacetylase/N-sulfotransferase activities have been cloned from a heparin-producing cell line MST from mouse (Orellana, A., Hirschberg, C.B., Wei, Z., Swiedler, S.J., and Ishihara M. , Journal of Biological Chemistry 21, pp. 2270-2276, 1994) and from a mouse mastocytoma cell line (Erikson, I., Sandback, D., Ek, B., Lindhal, U., and Kjellen, L. , Journal of Biological Chemistry 14, pp. 10438-10443, 1994).
In order to produce heparin in cell lines that do not normally produce heparin, it might be of great interest to express an enzyme that contains glycosaminoglycan N-acetylglucosaminyl N deacetylase/N-sulfo- transferase activities in these cells. For this, the cDNA coding for a glycosaminoglycan N-acetylglucosami- nyl N-deacetylase/N-sulfotransferase is incorporated into a plasmid or any suitable DNA sequence under the control of a viral or an eukaryotic promoter, thus allowing transcription of the corresponding RNA in these cells. This promoter can be an inducible promoter or a constitutive promoter. Targeting of the cells in order to incorporate the glycosaminoglycan N-acetylglu-
cosaminyl N-deacetylase/N-sulfotransferase cDNA can be performed by gene therapy using retroviral vectors, adenoviral vectors, or liposome-mediated gene delivery. While the invention has been described in con- nection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.
Claims
1. A method of inhibiting cap-independent protein synthesis of eukaryotic cells, which comprises adding heparin or heparin mimetics thereof to said eukaryotic cells .
2. The method of claim 1, wherein said heparin mimetic is sulfated polysaccharides .
3. A method of inhibiting translation of HIV TAR- containing messenger ribonucleic acids (mRNA) of HIV infected eukaryotic cells, which comprises adding heparin or heparin mimetics thereof to said eukaryotic cells.
4. A pharmaceutical composition for the therapeutical inhibition of cap-independent protein synthesis in a patient suffering from a viral infection, which comprises a therapeutic amount of heparin and/or heparin mimetics thereof in association with a pharmaceutical carrier.
5. The composition of claim 4, wherein said carrier is a liposome or a biovector.
6. A pharmaceutical composition for the therapeutical inhibition of translation of HIV TAR-containing messenger ribonucleic acids (mRNA) in a HIV-infected patient, which comprises a therapeutic amount of heparin and/or heparin mimetics thereof in association with a pharmaceutical carrier.
7. The composition of claim 6, wherein said carrier is a liposome or a biovector.
8. A composition for gene therapy of patients infected with a virus, which comprises administering to said patient an expression vector consisting of a cDNA sequence coding for enzyme glycosaminoglycan N-acetyl- glucosaminyl N-deacetylase/N-sulfotransferase with a constitutive or inducible promoter operatively linked upstream of the cDNA sequence, said expression vector is adapted to express said enzyme thereby reducing viral protein synthesis in said patient.
9. The composition of claim 8, wherein the expression vector is a recombinant virus selected from the group consisting of adenovirus and retrovirus for targeting of the infected cells.
10. The composition of claim 8, wherein the delivery vector is a liposome for targeting of the infected cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU47691/97A AU4769197A (en) | 1996-10-22 | 1997-10-21 | Inhibition of cap-independent protein synthesis by heparin or heparin mimetics thereof |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2873696P | 1996-10-22 | 1996-10-22 | |
| US60/028,736 | 1996-10-22 | ||
| US3201896P | 1996-11-22 | 1996-11-22 | |
| US60/032,018 | 1996-11-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1998017284A2 true WO1998017284A2 (en) | 1998-04-30 |
| WO1998017284A3 WO1998017284A3 (en) | 1998-08-20 |
Family
ID=26704031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CA1997/000794 WO1998017284A2 (en) | 1996-10-22 | 1997-10-21 | Inhibition of cap-independent protein synthesis and hiv-tar translation by heparin or heparin mimetics, and methods for gene therapy |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU4769197A (en) |
| WO (1) | WO1998017284A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6846917B2 (en) | 2001-01-23 | 2005-01-25 | Massachusetts Institute Of Technology | Solid- and solution-phase synthesis of heparin and other glycosaminoglycans |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| JPS59222410A (en) * | 1983-06-01 | 1984-12-14 | Terumo Corp | Pharmaceutical preparation of liposome for keeping drug |
| DE4121389A1 (en) * | 1991-02-07 | 1992-08-13 | Nattermann A & Cie | PHARMACEUTICAL PRODUCT FOR TREATING VIRUS DISEASES |
| JPH07145038A (en) * | 1993-11-26 | 1995-06-06 | Terumo Corp | Constituent component for membrane of small closed cell |
| JPH0827030A (en) * | 1994-07-08 | 1996-01-30 | Terumo Corp | Medicine carrier recognizing kidney |
-
1997
- 1997-10-21 WO PCT/CA1997/000794 patent/WO1998017284A2/en active Application Filing
- 1997-10-21 AU AU47691/97A patent/AU4769197A/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6846917B2 (en) | 2001-01-23 | 2005-01-25 | Massachusetts Institute Of Technology | Solid- and solution-phase synthesis of heparin and other glycosaminoglycans |
Also Published As
| Publication number | Publication date |
|---|---|
| AU4769197A (en) | 1998-05-15 |
| WO1998017284A3 (en) | 1998-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12274743B2 (en) | Nucleic acid vaccines | |
| US10815291B2 (en) | Polynucleotides encoding immune modulating polypeptides | |
| Takeshita et al. | Cloning of the γ chain of the human IL-2 receptor | |
| Kondratyev et al. | Identification and characterization of a radiation-inducible glycosylated human early-response gene | |
| US7423139B2 (en) | High level expression of recombinant human erythropoietin having a modified 5′-UTR | |
| WO2004101619A1 (en) | Rational design and synthesis of functional glycopeptide | |
| EP3076994A2 (en) | Targeted adaptive vaccines | |
| EP3043826A1 (en) | Polynucleotide compositions containing amino acids | |
| Takano et al. | Functional sites of the Ada regulatory protein of Escherichia coli: analysis by amino acid substitutions | |
| Maitra et al. | Termination, release, and reinitiation of RNA chains from DNA templates by Escherichia coli RNA polymerase | |
| WO1998017284A2 (en) | Inhibition of cap-independent protein synthesis and hiv-tar translation by heparin or heparin mimetics, and methods for gene therapy | |
| TWI283582B (en) | Expression potentiator for protein synthesis regulatory gene | |
| US5908923A (en) | Method of using transdominant negative retroviral integrase in the treatment of retroviral infection | |
| SEN | Transcriptional regulation of interferon-inducible genes | |
| Dr. Ikeda et al. | cDNA and deduced amino acid sequence of mouse matrix gla protein: one of five glutamic acid residues potentially modified to gla is not conserved in the mouse sequence | |
| RU94041110A (en) | Method of preparing dna-base antiviral preparation | |
| WO1996034009A1 (en) | Chimeric nucleic acids and proteins for inhibiting hiv-1 expression | |
| Barcellini-Couget et al. | 3′-End modification of the adenoviral VA1 gene affects its expression in human cells: consequences for the design of chimeric VA1 RNA ribozymes | |
| JP3476509B2 (en) | Hairpin ribozyme with thermodynamically stable loop | |
| Bienz-Tadmor | Analysis of the Gene Coding for the Murine P53 | |
| JP2577091C (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |